← Human Trials & Peer-Reviewed Studies
Long-Term experience with growth hormone therapy in pediatric growth disorders: an analysis of the LG growth study data.
Plain-language guide to PMID 41493505 (2026): multicenter observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 3,103 patients.
Key Facts
- PMID
- 41493505
- Journal
- Endocrine
- Year
- 2026
- Study type
- Observational Study
- Authors
- Lee HS et al. (10 authors)
- DOI
- 10.1007/s12020-025-04535-x
- Registered trial
- NCT01604395
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this observational study publication.
This study aimed to evaluate long-term growth outcomes of recombinant human GH therapy across various indications in Korean pediatric patients.
Why It Was Studied
METHODS: the researchers conducted a retrospective analysis utilizing 10-year longitudinal clinical data from the LG Growth Study (LGS), a multicenter, observational registry in Korea.
Annual changes in height standard deviation scores (SDS) and growth velocity were primary outcomes, with subgroup analyses by age at initiation and diagnosis performed to identify determinants of treatment response.
Who Took Part
The study group was 3,103 patients.
The age groups tagged for this paper are young children, children and teenagers, both men and women.
RESULTS: As of December 2022, a total of 3,103 patients were included in the analysis.
How the Study Was Run
The design is described as multicenter.
More than one site took part, so the patients came from several places.
What Was Measured
Annual changes in height standard deviation scores (SDS) and growth velocity were primary outcomes, with subgroup analyses by age at initiation and diagnosis performed to identify determinants of treatment response.
PubMed files the paper under topics including Human Growth Hormone, Growth Disorders, Turner Syndrome, Infant, Small for Gestational Age, Body Height, Republic of Korea and Longitudinal Studies.
The authors tagged it with the keywords Growth hormone deficiency, Short stature and Treatment.
What This Means in Plain Language
The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 3,103 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2026 (Endocrine), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.